Skip to content Skip to navigation

Announcement:

Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma

New Blog Post:

First-in-Human Results for GB-0669: Durable Neutralization from an AI-Designed Antibody

Flagship Pioneering
  • Generative Biology™
  • Platform
  • Pipeline
  • About Us
  • Careers
  • Media Center
  • Contact
  • LinkedIn
  • X
  • YouTube
Media Highlights

Generate Named to 2022 Forbes AI 50 List

Forbes 05.11.2022
  • Generative Biology™
  • Platform
  • Pipeline
  • About Us
  • Careers
  • Media Center
  • Contact
Now we can.

Generate:Biomedicines

101 South Street, Suite 900
Somerville, MA 02143

United States

© 2025 Generate:Biomedicines
  • LinkedIn
  • X
  • YouTube
Privacy Policy Terms of Use Cookie Settings